In a production method of the present disclosure, a 1,1-binaphthyl precursor derivative, an organic acid, and an iodinating or brominating agent are mixed. The 1,1-binaphthyl precursor derivative has a 1,1-binaphthyl skeleton and has an electron-donating group at the 2-position of the 1,1-binaphthyl skeleton and at the 2-position of the 1,1-binaphthyl skeleton, and the electron-donating group contains an oxygen atom directly bonded to the skeleton. With the production method of the present disclosure, a 1,1-binaphthyl derivative having a substituent introduced at the 8-position and/or 8-position of the 1,1-binaphthyl skeleton can be obtained. The 1,1-binaphthyl derivative obtained by the production method of the present disclosure can be a compound further having a substituent introduced at at least one position selected from the 4-position, 4-position, 5-position, 5-position, 6-position, and 6-position of the 1,1-binaphthyl skeleton.

Provided is a method the enables easy production of bis(fluorosulfonyl)imide suitable for a non-aqueous electrolytic solution for a lithium ion secondary battery, etc. The method for producing a bis(fluorosulfonyl)imide alkali metal salt according to the present invention comprises reacting bis(fluorosulfonyl)imide with an alkali metal compound in a reaction solution containing an organic solvent, wherein the organic solvent includes at least one organic solvent (A) selected from the group consisting of carbonate solvents, cyclic ether solvents, linear ether solvents having two or more oxygen atoms in the molecule, cyclic ester solvents, sulfolane solvents, N,N-dimethyl formamide, dimethyl sulfoxide, and N-methyl oxazolidinone.

Provided is a method with which it is possible to conveniently produce bis(fluorosulfonyl)imide suitable as a nonaqueous electrolyte of a lithium ion secondary cell. The method for producing a bis(fluorosulfonyl)imide alkali metal salt of the invention is a production method for producing a bis(fluorosulfonyl)imide alkali metal salt by reacting bis(fluorosulfonyl)imide and an alkali metal halide in a reaction solution including an organic solvent, the method including a purification step for filtering out the bis(fluorosulfonyl)imide alkali metal from the solution after the reaction.

The invention relates to a novel crystallization process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronization. Said process comprises the step of dissolving fluticasone propionate in acetone or in a mixture of acetone and water and then adding this solution to water or to a mixture of water 10 and acetone, thereby causing fluticasone propionate to crystallize out of the solution as crystalline form.

Provided is an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl](2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. It also relates to highly pure novel crystalline form of Isosulfan blue hydrate and its process for the preparation thereof. It also relates to an improved process for the preparation of Isosulfan blue sodium hydrate having not more than 0.2% of desethyl impurity of formula A.

##STR00001##

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention concerns a method for preparing an oxysulphide and fluorinated derivative of formula (III) Ea-SO.sub.3R (III) that comprises bringing a compound of formula (II) Ea-SOOR (II)Ea representing the fluorine atom or a group having 1 to 10 carbon atoms chosen from the fluoroalkyls, the perfluoroalkyls and the fluoroalkenyls; andR representing hydrogen, a monovalent cation or an alkyl group; into contact, in the presence of a polar aprotic organic solvent, with an oxidising agent.

The present invention concerns a method for preparing an oxysulphide and fluorinated derivative of formula (III) Ea-SO.sub.3R (III) that comprises bringing a compound of formula (II) Ea-SOOR (II)Ea representing the fluorine atom or a group having 1 to 10 carbon atoms chosen from the fluoroalkyls, the perfluoroalkyls and the fluoroalkenyls; andR representing hydrogen, a monovalent cation or an alkyl group; into contact, in the presence of a polar aprotic organic solvent, with an oxidising agent.

The present invention concerns a method for preparing an oxysulphide and fluorinated derivative of formula (III) Ea-SO.sub.3R (III) that comprises bringing a compound of formula (II) Ea-SOOR (II)Ea representing the fluorine atom or a group having 1 to 10 carbon atoms chosen from the fluoroalkyls, the perfluoroalkyls and the fluoroalkenyls; andR representing hydrogen, a monovalent cation or an alkyl group; into contact, in the presence of a polar aprotic organic solvent, with an oxidising agent.